Senologie - Zeitschrift für Mammadiagnostik und -therapie, Table of Contents Senologie - Zeitschrift für Mammadiagnostik und -therapie 2022; 19(01): 26-29DOI: 10.1055/a-1768-6610 Gesellschaftsmitteilungen Tamoxifen – Lieferengpass: Eine Stellungnahme der Fachgesellschaft Recommend Article Abstract Buy Article(opens in new window) Full Text References Literatur 1 Early Breast Cancer Trialist's Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341-1352 2 Legha SS, Davis HL, Muggia FM. Hormonal therapy of breast cancer: new approaches and concepts. Ann Inten Med 1978; 88: 69-77 3 Baum M, Brinkley DM, Dossett JA. et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 322: 405 4 Early Breast Cancer Trialist's Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28896 women. N Engl J Med 1988; 319: 1681-1692 5 AWMF. S3-Leitlinie „Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms“, Juni 2021. Registernummer 032-045OL. https://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2020-02.pdf 6 Arbeitsgemeinschaft Gynäkologische Onkologie. Diagnostik und Therapie primärer und metastasierter Mammakarzinome: Endokrine und zielgerichtete Therapie metastasiertes Mammakarzinom. März 2021. https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2021/Einzeldateien_Literatur/2021D_10_Adjuvante_Endokrine_Therapie_MASTER_final_20210302_inklREf.pdf 7 Mammakarzinom der Frau. Leitlinien von DGHO, OeGHO, SGMO und SGH+SSH, Status Januar 2018. http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/mammakarzinom-der-frau 8 Weichgewebssarkome (maligne Weichgewebstumoren) des Erwachsenen. Onkopedia, April 2019. https://www.onkopedia.com/de/onkopedia/guidelines/weichgewebssarkome-maligne-weichgewebstumoren-des-erwachsenen/@@guideline/html/index.html 9 AWMF. S3-Leitlinie Prostatakarzinom, Oktober 2021. https://www.awmf.org/uploads/tx_szleitlinien/043-022OLl_S3_Prostatakarzinom_2021-10.pdf 10 Cardoso F, Paluch-Shimon F, Senkus E. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31: 1623-1649 11 Chlebowski RT, Pan K, Col NF. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. Breast Cancer Res Treat 2017; 161: 185-190 12 Hackshaw A, Baum M, Fornander T. et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009; 101: 341-349 13 Goss PE, Ingle JN, Pater JL. et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26: 1948-1955 14 Early Breast Cancer Trialists‘ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet 2011; 378: 771-784 15 Early Breast Cancer Trialist's Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341-1352 16 Rugo HS, Rumble RB, Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103 17 Kasper B, Baumgarten C, Garcia J. on behalf of the Desmoid Working Group. et al. An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between Sarcoma Patients EuroNet (SPAEN) and European Organisation for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 2017; 28: 2399-2408 18 Janinis J, Patriki M, Vini L. et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14: 181-190 19 Iversen P, Tammela TLJ, Vaage S. et al. A Randomised Comparison of Bicalutamide (‚Casodex‘) 150 Mg Versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non- Metastatic Prostate Cancer. First Report from the Scandinavian Prostatic Cancer Group Study 6. Eur Urol 2002; 42: 204-211 20 Perdonà S, Autorino R, De Placido S. et al. Efficacy of Tamoxifen and Radiotherapy for Prevention and Treatment of Gynaecomastia and Breast Pain Caused by Bicalutamide in Prostate Cancer: A Randomised Controlled Trial. Lancet Oncol 2005; 6: 295-300 21 Williams C, Simera CI, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2010; (03) CD001034 22 AWMF. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. https://www.awmf.org/uploads/tx_szleitlinien/032-035OLl_S3_Diagnostik-Therapie-Nachsorge-maligner-Ovarialtumoren_2021-10.pdf
